Rafarma – MTP Partnership to Open Specialized Spas Offering Cannabis Treatments in Thailand
Following on the recently-announced partnership between Rafarma Pharmaceuticals Inc. (OTC: RAFA), and Thailand’s MTP Material Co. Ltd., Rafarma is pleased to announce the commencement of its Specialized Detox Centers project in Thailand. The company and its partners are currently in search of a suitable location for a pilot spa in Phuket, Thailand.
Through active cooperation with Khon Kaen University and Dr. Monchai Duangjinda‘s team of researchers, the company intends to develop cannabis-based spa protocols to treat patients in a variety of areas including wound healing, pain management after illness or surgery, rehabilitation, expectoration, stress management, depression management and sleep disorders management.
On February 20, 2019 Thailand’s king signed a royal decree legalizing marijuana for medical uses, allowing doctors, patients, schools, farmers, entrepreneurs and exporters to cultivate, possess and dispense cannabis. King Maha Vajiralongkorn signed the medical measure two months after the military government’s parliament unanimously approved it, a legislative sequence required by the constitution.
Based on the new version of the law, the Thailand Ministry of Health has undertaken several acts that allow for storage of cannabis for medical purposes (including rehabilitation treatment) and for research. Thailand is one of the first countries in Asia pursuing legal reforms to allow cannabis usage for multiple purposes.
The company will employ scientists that practice traditional Thai medicine (the Thai spa industry), as well as traditional medical doctors in order to develop the best spa procedures using the healing qualities of cannabis.
The company also intends to introduce the concept of ‘detox restaurants’ that will address the same health issues as the specialized detox spas.
This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
SOURCE: Rafarma Pharmaceuticals, Inc.